• Journal Article

Redesigning the DNA-Targeted Chromophore in Platinum-Acridine Anticancer Agents: A Structure-Activity Relationship Study

Citation

Pickard, A. J., Liu, F., Bartenstein, T. F., Haines, L., Levine, K., Kucera, G. L., & Bierbach, U. (2014). Redesigning the DNA-Targeted Chromophore in Platinum-Acridine Anticancer Agents: A Structure-Activity Relationship Study. Chemistry-A European Journal, 20(49), 16174-16187. DOI: 10.1002/chem.201404845

Abstract

Platinum-acridine hybrid agents show low-nanomolar potency in chemoresistant non-small cell lung cancer (NSCLC), but high systemic toxicity in vivo. To reduce the promiscuous genotoxicity of these agents and improve their pharmacological properties, a modular build-click-screen approach was used to evaluate a small library of twenty hybrid agents containing truncated and extended chromophores of varying basicities. Selected derivatives were resynthesized and tested in five NSCLC cell lines representing large cell, squamous cell, and adenocarcinomas. 7-Aminobenz[c]acridine was identified as a promising scaffold in a hybrid agent (P1-B1) that maintained submicromolar activity in several of the DNA-repair proficient and p53-mutant cancer models, while showing improved tolerability in mice by 32-fold compared to the parent platinum-acridine (P1-A1). The distribution and DNA/RNA adduct levels produced by the acridine- and benz[c]acridine-based analogues in NCI-H460 cells (confocal microscopy, ICP-MS), and their ability to bind G-quadruplex forming DNA sequences (CD spectroscopy, HR-ESMS) were studied. P1-B1 emerges as a less genotoxic, more tolerable, and potentially more target-selective hybrid agent than P1-A1